Table 1.
Clinical data at baseline and after transplantation in relation to glycemic status 1 year after kidney transplantation
| 12-Months OGTT | No Diabetes |
NODM | OR (95% Confidence Interval) |
||
|---|---|---|---|---|---|
| NGT | Prediabetes | Crude | Adjusted | ||
| n | 32 | 17 | 8 | ||
| Age, yr | 35 ± 12 | 45 ± 12 | 44 ± 12 | 1.06 (1.02 to 1.11) | 1.06 (1.01 to 1.11) |
| Gender, male/female | 20/12 | 14/3 | 4/4 | 1.20 (0.41 to 3.52) | |
| Family history of diabetes, n | 0 | 2 | 0 | 2.99 (0.2 to 40.7) | |
| BMI, kg/m2 | 23.6 ± 3.3 | 24.9 ± 4.7 | 26.7 ± 3.4 | 1.14 (0.99 to 1.31) | |
| Change in BMI, kg/m2 | 1.8 ± 2.5 | 2.3 ± 1.4 | 1.1 ± 1.7 | 0.97 (0.76 to 1.24) | |
| MAP, mmHg | 103 ± 12 | 102 ± 14 | 109 ± 20 | 1.01 (0.98 to 1.09) | |
| Waist-hip ratio | 0.91 ± 0.09 | 0.93 ± 0.08 | 0.95 ± 0.1 | 0.88 (0.27 to 2.91) | |
| Change in waist-hip ratio | 0.0 ± 0.1 | 0.1 ± 0.2 | 0.0 ± 0.1 | 10.1 (0.1 to 891) | |
| Baseline ISI | 7.9 ± 3.3 | 5.9 ± 4.9 | 4.2 ± 1.6 | 0.82 (0.69 to 0.97) | 0.83 (0.70 to 0.98) |
| Baseline Isecr | 31.6 ± 14.4 | 42.9 ± 22.5 | 46.0 ± 19.0 | 1.03 (1.01 to 1.06) | |
| Former Tx, n (%) | 8 (25) | 3 (18) | 0 | 0.36 (0.08 to 1.55) | |
| Rejections, n (%) | 3 (9) | 4 (24) | 2 (25) | 2.63 (0.69 to 10.06) | |
| ESRD, mo, median (range) | 7 (0 to 134) | 25 (0 to 108) | 30 (5 to 48) | 1.02 (1.00 to 1.03) | |
| CMV IgG, n (%) | 21 (66) | 11 (65) | 7 (88) | 1.19 (0.40 to 3.49) | |
| Accumulated prednisolone dose within 90 days, g | 2.39 ± 1.26 | 2.93 ± 1.20 | 2.93 ± 1.65 | 1.34 (0.91 to 2.08) | |
| Use of tacrolimus at Tx, n (%) | 7 (22) | 4 (24) | 3 (37) | 1.54 (0.49 to 4.86) | |
Values are given as mean ± SD unless otherwise noted. NGT, normal glucose tolerance; NODM, new onset diabetes mellitus; Tx, kidney transplantation; CMV, cytomegalovirus.